Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: peripherally acting cannabinoid receptor CB1 antagonists - Corbus Pharmaceuticals

Drug Profile

Research programme: peripherally acting cannabinoid receptor CB1 antagonists - Corbus Pharmaceuticals

Alternative Names: CRB 4001; JD-2000 series; JD-2114; JD-5000 series; JD-5006; JD-5037; JD-6000 series

Latest Information Update: 16 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jenrin Discovery
  • Developer Corbus Pharmaceuticals; Jenrin Discovery; National Institutes of Health (USA)
  • Class Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Hepatoprotectants; Obesity therapies; Small molecules
  • Mechanism of Action Cannabinoid 1 receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Bile duct diseases; Diabetic nephropathies; Fibrosis; Hyperlipidaemia; Insulin resistance; Nephritis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 08 Nov 2018 Preclinical trials in Diabetic nephropathies in USA (unspecified route)
  • 08 Nov 2018 Preclinical trials in Insulin resistance in USA (unspecified route)
  • 20 Sep 2018 Corbus Pharmaceuticals plans a first-in-patient phase II trial (NIH funded) for CRB 4001 in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top